登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>Claudin-6 >CL6-H5286

Human Claudin-6 / CLDN6 Full Length Protein, His,Twin-Strep Tag (Nanodisc)

分子别名(Synonym)

Claudin-6,CLDN6

表达区间及表达系统(Source)

Human Claudin-6 Protein, His,Twin-Strep Tag (CL6-H5286) is expressed from Baculovirus-Insect cells. It contains AA Ala 2 - Val 220 (Accession # P56747).

Predicted N-terminus: Met

Request for sequence

蛋白结构(Molecular Characterization)

Claudin-6 Structure

This protein carries a polyhistidine tag at the N-terminus and a twin strep tag at the C-terminus.

The protein has a calculated MW of 28.3 kDa. The protein migrates as 23-28 kDa under reducing (R) condition (SDS-PAGE).

Nanodiscs are a new class of model membranes that are being used to solubilize and study a range of integral membrane proteins and membrane-associated proteins. The Nanodisc bilayer is bounded by a membrane scaffold protein (MSP1D1) coat that confers enhanced stability and a narrow particle size distribution.

The nanodisc assembles from a mixture of full length membrane protein in detergent, phospholipid micelles and membrane scaffold protein(MSP1D1) upon removal of the detergent.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

制剂(Formulation)

Supplied as 0.2 μm filtered solution in 20 mM HEPES, 150 mM NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

运输(Shipping)

This product is supplied and shipped with dry ice, please inquire the shipping cost.

存储(Storage)

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. The product MUST be stored at -70°C or lower upon receipt;
  2. -70°C for 12 months under sterile conditions.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
*The isotype control of empty/mock nanodisc (Cat. No. APO-H51H3) is sold separately and not included in protein, you can follow this link for product information.
 

电泳(SDS-PAGE)

Claudin-6 SDS-PAGE

Human Claudin-6 Protein, His,Twin-Strep Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

 

活性(Bioactivity)-ELISA

Claudin-6 ELISA

Immobilized Human Claudin-6 Protein, His,Twin-Strep Tag (Cat. No. CL6-H5286) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Human Claudin-6 antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (QC tested).

Protocol

 

活性(Bioactivity)-SPR

Claudin-6 SPR

Anti-Claudin-6 Antibody, Human IgG1 captured on Protein A Chip can bind Human Claudin-6 Protein, His,Twin-Strep Tag (Cat. No. CL6-H5286) with an affinity constant of 1.08 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol

 

CAR阳性表达率检测(Evaluation of CAR expression)

FACS Analysis of Anti-Claudin-6 CAR Expression

Claudin-6 CAR_T

2e5 of anti-Claudin-6 (AE49-11) CAR-293 cells were stained with 100 μL of 10 μg/mL of Human Claudin-6 Protein, His,Twin-Strep Tag (Cat. No. CL6-H5286) and negative control protein respectively (Fig. A and B), FITC signal was used to evaluate the binding activity (QC tested).

FACS Analysis of Non-specific binding to PBMCs

Claudin-6 CAR_T

5e5 of PBMCs were stained with Human Claudin-6 Protein, His,Twin-Strep Tag (Cat. No. CL6-H5286) and anti-CD3 antibody, washed and then analyzed with FACS. PE signal was used to evaluate the expression of CD3+ T cells in PBMCs, and FITC signal was used to evaluate the non-specific binding activity to PBMCs (QC tested).

 
评论(1)
  1. 155XXXXXXX7
  2. 0人赞
  3. 购买这款蛋白主要是为了早期筛选做准备,够了两个批次的产品,不同批次间差异很小,几乎可以忽略不记。总之实验很顺利,会一直支持
  4. 2025-2-8
 
ACRO质量管理体系
 
 

背景(Background)

Tight junctions represent one mode of cell-to-cell adhesion in epithelial or endothelial cell sheets, forming continuous seals around cells and serving as a physical barrier to prevent solutes and water from passing freely through the paracellular space. These junctions are comprised of sets of continuous networking strands in the outwardly facing cytoplasmic leaflet, with complementary grooves in the inwardly facing extracytoplasmic leaflet. Claudin-6, also knows as CLDN6, is a multipass transmembrane protein in the Claudin family. Claudin-6 is expressed by epithelial cells where it participates in tissue development and the maintenance of tight junction integrity. And it is one of the entry cofactors for hepatitis C virus. The methylation of CLDN6 may be involved in esophageal tumorigenesis. The gene of CLDN6 is adjacent to another family member CLDN9 on chromosome 16.

 

前沿进展

The Chimeric Antigen Receptor T Cell Target Claudin 6 Is a Marker for Early Organ-Specific Epithelial Progenitors and Is Expressed in Some Pediatric Solid Tumor Entities
Seidmann, Wingerter, Oliver Metzig et al
Cancers (Basel) (2025) 17 (6)
Abstract: Background/Objectives: The oncofetal membrane protein Claudin 6 (CLDN6) is an attractive target for T cell-based therapies. There is a lack of detailed analyses on the age-dependent expression of CLDN6 in normal tissues is lacking, which limits the expansion of CLDN6 CAR-T cell clinical trials to pediatric populations. Methods: We analyzed CLDN6 expression in extracranial solid tumors and normal tissues of children using RNA-sequencing data from over 500 pediatric solid tumor samples, qRT-PCR and immunohistochemistry (IHC) in more than 100 fresh-frozen tumor samples and, approximately, 250 formalin-fixed paraffin-embedded (FFPE) samples. We examined normal tissue expression via qRT-PCR in 32 different infant tissues and via IHC in roughly 290 tissues from donors across four age groups, as well as in fetal autopsy samples. Results: In fetal tissues, we detected CLDN6 expression primarily in the epithelial cells of several organs, including the skin, lungs, kidneys, intestinal tract, and pancreas, but not in undifferentiated blastemal cells. Postnatally, we found CLDN6-positive epithelial progenitors only during the first few weeks of life. In older-age groups, isolated clusters of CLDN6-positive progenitors were present, but in scarce quantities. In tumor tissues, we found strong and homogeneous CLDN6 expression in desmoplastic small round cell tumors and germ cell tumors. Wilms tumors demonstrated heterogeneous CLDN6 expression, notably absent in the blastemal component. Conclusions: These findings highlight an organ-specific presence of CLDN6-positive epithelial precursors that largely disappear in terminally differentiated epithelia within weeks after birth. Therefore, our data support CLDN6 as a viable therapeutic target in pediatric patients and justify their inclusion in basket studies for anti-CLDN6-based therapies.
A mini-overview of antibody-drug conjugates in platinum-resistant ovarian cancer: A preclinical and clinical perspective
Zhao, Yuan, Li et al
Int J Biol Macromol (2025) 304 (Pt 2), 140767
Abstract: Ovarian cancer is one of the most lethal gynaecologic cancers in China. Although platinum-based chemotherapy, PARP inhibitors and bevacizumab have prolonged long term survival and increased the overall response rate for platinum-sensitive ovarian cancer (PSOC), the treatment options for platinum-resistant ovarian cancer (PROC) are still limited. Antibody-drug conjugates (ADCs) represent a novel form of precision medicine, covalently linking specific monoclonal antibodies with potent cytotoxic payloads. Since mirvetuximab soravtansine (MIRV) received approval by the US Food and Drug Administration (FDA) as the first ADC for PROC in 2022, the development of novel ADCs for various targets in PROC has accelerated. In this review, we summarise the recent evidence and future prospects of ADCs targeting Folate Receptor alpha (FRα), mesothelin, cadherin-6, NaPi2b, human epidermal growth factor receptor 2 (HER2), dipeptidase 3 (DPEP3), B7-H4 (VTCN1), claudin-6 (CLDN6) and trophoblast antigen protein 2 (TROP2), in order to enhance our understanding of the clinical applications of ADCs and offer new insights for clinical practice and further research.Copyright © 2025. Published by Elsevier B.V.
177Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer
Du, Hao, Lin et al
J Nucl Med (2025) 66 (3), 377-384
Abstract: Advanced or metastatic esophageal cancer (EC) is associated with poor prognosis, necessitating new and effective treatment methods. We assess whether claudin 6 (CLDN6) is a useful target for the imaging and radiopharmaceutical therapy of EC using a novel pair of radioactive nuclides, 89Zr and 177Lu. Methods: CLDN6 messenger RNA expression was evaluated in 2 EC datasets (n = 436) and through a retrospective analysis of 109 patients with EC. We then used an anti-CLDN6 monoclonal antibody (IMAB027) labeled with 89Zr and 177Lu ([89Zr]Zr-DFO-IMAB027 and [177Lu]Lu-DOTA-IMAB027) for PET imaging and therapy, respectively. Imaging and biodistribution analyses were performed using the TE-1-CLDN6 xenograft model. Finally, the therapeutic potential of [177Lu]Lu-DOTA-IMAB027 was evaluated in both the TE-1-CLDN6 and the CLDN6-PDX (patient-derived xenograft) models. Results: CLDN6 messenger RNA expression was elevated in EC compared with healthy esophageal tissues. The CLDN6 expression rate was 0 in healthy esophageal tissue but was 79.8% in EC tissue. The [89Zr]Zr-DFO-IMAB027 showed the ability to effectively image EC xenografts with high CLDN6 expression. In the TE-1-CLDN6 model, there was a significant difference in tumor volume between the 11.1-MBq [177Lu]Lu-DOTA-IMAB027 treatment group and the control group (P < 0.001). The tumor growth inhibition rate in the 11.1-MBq [177Lu]Lu-DOTA-IMAB027 group was 101.74%. In the PDX model, significant differences in tumor volume were observed among all [177Lu]Lu-DOTA-IMAB027 treatment groups and the control group (P < 0.05). Specifically, the tumor growth inhibition rate of the 11.1-MBq [177Lu]Lu-DOTA-IMAB027 group was 79.04%, whereas that of the 3.7-MBq group was 77.20%. However, the difference in efficacy between the high-dose and low-dose groups was not statistically significant (P > 0.05). Conclusion: The differential expression of CLDN6 between tumors and the normal esophagus shows its potential as a diagnostic and therapeutic target for EC. The radiotracer [89Zr]Zr-DFO-IMAB027 showed high contrast when visualizing CLDN6-expressing xenografts for PET imaging, and [177Lu]Lu-DOTA-IMAB027 induced rapid tumor regression in both the TE-1-CLDN6 and the CLDN6-PDX models. This research has implications for improving the radioligand diagnosis and treatment of EC.© 2025 by the Society of Nuclear Medicine and Molecular Imaging.
Clinicopathological Significance of Claudin-6 Immunoreactivity in Low-grade, Early-stage Endometrioid Endometrial Carcinoma
Lee, Kim
In Vivo (2025) 39 (1), 367-374
Abstract: Dysregulation of claudin 6 (CLDN6) expression has been widely documented in various malignancies. CLDN6 is aberrantly expressed in many types of human carcinomas; however, its clinical significance in endometrial carcinoma has seldom been investigated. This study aimed to examine the immunohistochemical expression status of CLDN6 in low-grade, early-stage endometrioid endometrial carcinoma (LGES-EEC) and to assess its clinicopathological significance.We performed immunostaining for CLDN6 in 118 tissue samples from LGES-EECs. Protein expression levels were interpreted using a semi-quantitative histoscore method. All statistical analyses were performed.CLDN6 was primarily localized along the membranes of the tumor cells. We considered histoscore ≥10 (the staining proportion ≥5% and intensity ≥2) as positive immunoreactivity for CLDN6. Twenty-six of the 118 patients (22.0%) showed CLDN6 positivity. Positive CLDN6 expression was significantly associated with deeper myometrial invasion (p=0.001), higher initial stage (p=0.015), and substantial lymphovascular space invasion (p=0.018).Aberrant CLDN6 expression is involved in tumor progression in LGES-EECs. In addition, targeting CLDN6 may offer clinical utility in patients with endometrial carcinoma.Copyright © 2025, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Showing 1-4 of 183 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Claudin-6靶点信息
英文全称:Claudin 6
中文全称:紧密连接蛋白6
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:10详情
最高研发阶段:临床二期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定